Off-label drug promotion in the US out of control?

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1650, 2008-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Criminal charges for off-label drug promotion?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 615, 2010-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Off-label or untested use of drug-eluting stents warranted?

By  

Inpharma, Vol. 1, Iss. 1587, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

FDA turning a blind eye to off-label drug use?

By  

Inpharma, Vol. 1, Iss. 1634, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Off-Label Use of Atypical Antipsychotics: Cause for Concern?

By McKean Andrew  

CNS Drugs, Vol. 26, Iss. 5, 2012-05 ,pp. : 383-390

Adis International

Access to resources Recommend Favorite

Legal and Economic Perspectives Concerning US Government Investigations of Alleged Off-Label Promotion by Drug Manufacturers

By Kalb Paul E.  

PharmacoEconomics, Vol. 27, Iss. 8, 2009-08 ,pp. : 623-625

Adis International

Access to resources Recommend Favorite